Supplemental Table 2.
Secondary outcomes by group among patients with critical disease
| Secondary outcome | Pregnant cases (n=29) |
Nonpregnant controls (n=80) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Mean±SD | Median (IQR) | Range | N | Mean±SD | Median (IQR) | Range | ||
| Length of stay | |||||||||
| Hospital length of stay (d)a | 9 | 13.3±7.9 | 12 (6–21) | 4–25 | 14 | 17.5±15.7 | 13 (7–25) | 2–53 | |
| ICU length of stay (d)b | 9 | 6.6±4.2 | 7 (4–9) | 1–13 | 10 | 13.4±13.3 | 9.5 (5–17) | 2–45 | |
| n/N (%) | n/N (%) | |
|---|---|---|
| ICU admission | 9/9 (100.0) | 10/14 (71.4) |
| Discharge disposition | ||
| Home without O2 requirement | 8/9 (88.9) | 7/14 (50.0) |
| SNF or LTAC or home with O2 or other requirement | 1/9 (11.1) | 4/14 (28.6) |
| Death | 0/9 (0.0) | 3/14 (21.4) |
| Morbidity during admission | ||
| Any morbidity | 9/9 (100.0) | 11/14 (78.6) |
| Sepsis | 2/9 (22.2) | 4/14 (28.6) |
| Cardiac arrest | 0/9 (0.0) | 3/14 (21.4) |
| ARDS | 5/9 (55.6) | 6/14 (42.9) |
| Ventilation | 8/9 (88.9) | 7/14 (50.0) |
| Tracheostomy | 2/9 (22.2) | 1/14 (7.1) |
| Blood product transfusion | 1/9 (11.1) | 0/14 (0.0) |
| AKI | 0/9 (0.0) | 1/14 (7.1) |
| Shock | 2/9 (22.2) | 4/14 (28.6) |
| Other morbidity | 0/9 (0.0) | 1/14 (7.1) |
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; ICU, intensive care unit; IQR, interquartile range; LTAC, long-term acute care; SD, standard deviation; SNF, skilled nursing facility.
DeBolt et al. Severe and critical COVID-19 in pregnant vs nonpregnant controls. Am J Obstet Gynecol 2021.
a
Hospital length of stay was log transformed and modeled using linear regression. The beta coefficient for cases was exponentiated to estimate the ratio of geometric means
b
ICU length of stay is only calculated for those 19 patients who were admitted to the ICU (pregnant cases and 10 nonpregnant controls).